These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 2503724)

  • 1. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
    N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo.
    Benson RC; Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Dorr FA
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):9-12. PubMed ID: 1948121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
    Crawford ED; Goodman P; Blumenstein B
    Semin Urol; 1990 Aug; 8(3):154-8. PubMed ID: 2119048
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leuprolide plus flutamide: combined androgen blockade in the treatment of advanced prostate cancer.
    Chodoff L
    Mt Sinai J Med; 1990 May; 57(3):171-3. PubMed ID: 2115128
    [No Abstract]   [Full Text] [Related]  

  • 6. Leuprolide with and without flutamide in advanced prostate cancer.
    Crawford ED; Blumenstein BA; Goodman PJ; Davis MA; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA
    Cancer; 1990 Sep; 66(5 Suppl):1039-44. PubMed ID: 2118417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone releasing hormone agonists: the US experience.
    Nabors W; Crawford ED
    J Int Med Res; 1990; 18 Suppl 1():31-4. PubMed ID: 2108884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flutamide approved for prostate cancer.
    Oncology (Williston Park); 1989 Mar; 3(3):135. PubMed ID: 2518157
    [No Abstract]   [Full Text] [Related]  

  • 10. Total androgen blockade: the United States experience.
    Benson RC
    Eur Urol; 1993; 24 Suppl 2():72-6. PubMed ID: 8262130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flutamide for prostate cancer.
    Med Lett Drugs Ther; 1989 Jul; 31(797):72. PubMed ID: 2501635
    [No Abstract]   [Full Text] [Related]  

  • 14. Duration of androgen suppression in the treatment of prostate cancer.
    Bolla M; de Reijke TM; Van Tienhoven G; Van den Bergh AC; Oddens J; Poortmans PM; Gez E; Kil P; Akdas A; Soete G; Kariakine O; van der Steen-Banasik EM; Musat E; Piérart M; Mauer ME; Collette L;
    N Engl J Med; 2009 Jun; 360(24):2516-27. PubMed ID: 19516032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total androgen ablation: American experience.
    Crawford ED; Nabors WL
    Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.
    Crawford ED; Allen JA
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):961-3. PubMed ID: 2126738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination studies with leuprolide.
    Crawford ED
    Eur Urol; 1990; 18 Suppl 3():30-3. PubMed ID: 2128828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
    Labrie F; Dupont A; Cusan L; Gomez J; Diamond P; Koutsilieris M; Suburu R; Fradet Y; Lemay M; Têtu B
    Clin Invest Med; 1993 Dec; 16(6):499-509. PubMed ID: 8013155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.